NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01. Other Events.
issued a press release titled “NewLink Genetics Indoximod
PROVENGE Results in Statistically Significant Improvement in
Radiographic Progression-Free Survival (rPFS) for Patients with
Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase
2 Trial.”
incorporated herein by reference.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated June 5, 2017, entitled NewLink
Genetics Indoximod PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial |
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
